BioCentury | Apr 26, 1999
Finance

The '$25 million and over club'

...Raised ($M)(a) Tularik 10/11/96 $60.0 Affymetrix 8/3/95 $39.0 Sequenom 4/19/99 $37.0 Medicines Co. 8/31/98 $36.0 Therexsys...
BioCentury | Feb 23, 1998
Company News

Cobra Biosciences Ltd., Therexsys deal

...worth 8 percent of Therexsys' shares outstanding, about £4 million (US$6.8 million), to Cobra's founders. Therexsys...
...Therexsys will change its name to Cobra Therapeutics Ltd. Cobra Biosciences Ltd. , Birmingham, U.K. Therexsys Ltd....
BioCentury | Feb 23, 1998
Company News

Therexsys board of directors update

Therexsys Ltd. , Keele, U.K. Business: Gene/Cell therapy Appointed: Michael Carter, EVP and board member of Salick Health Care Inc. WIR Staff...
BioCentury | Dec 15, 1997
Company News

Therexsys management update

Therexsys Ltd., Staffordshire, U.K. Business: Gene/Cell therapy Hired: David Bloxham as CEO, formerly COO of Celltech plc WIR Staff...
BioCentury | Jul 15, 1996
Clinical News

Therexsys regulatory update

...Therexsys said U.S. Patent No. 5,532,143 issued covering its Locus Control Region (LCR) technology. Therexsys has...
...ensure that the introduced gene is expressed in target cells and not in other cells. Therexsys Ltd....
BioCentury | May 6, 1996
Emerging Company Profile

Gryphon Sciences

...Kent, plus Robin Offord and Keith Rose Corporate partners: Icos Corp. , SmithKline Beecham and Therexsys Ltd....
BioCentury | May 6, 1996
Emerging Company Profile

Gryphon: People make proteins

...the vaccine or gene therapy markets only with partners. Grphyon has an ongoing collaboration with Therexsys Ltd....
BioCentury | Dec 4, 1995
Company News

Therexsys other research news

...the manufacture of gene-based medicines. Therexsys is developing non-viral, targeted and regulated gene delivery systems. Therexsys Ltd....
BioCentury | Sep 25, 1995
Emerging Company Profile

Therexsys Ltd.

Therexsys Ltd. Keele, U.K. Technology: Nonviral gene therapy Founded: 1992 by Roger Craig, Frank Grosveld, Michael Dexter, the Medical Research Council (U.K.) and the Cancer Research Campaign (U.K.) University collaborators: Erasmus University (Rotterdam) Corporate partners:...
BioCentury | Sep 25, 1995
Emerging Company Profile

Therexsys: Regulated expression

...to deliver genes successfully is the regulation of expression of the genes in target cells. Therexsys Ltd....
...genes to be transcribed. Thus the LCR technology enables protein expression in specific cells, giving Therexsys...
...of position. Grosveld, now at Erasmus University (Rotterdam), is continuing to collaborate with Therexsys. Self-assembly Therexsys...
Items per page:
1 - 10 of 14
BioCentury | Apr 26, 1999
Finance

The '$25 million and over club'

...Raised ($M)(a) Tularik 10/11/96 $60.0 Affymetrix 8/3/95 $39.0 Sequenom 4/19/99 $37.0 Medicines Co. 8/31/98 $36.0 Therexsys...
BioCentury | Feb 23, 1998
Company News

Cobra Biosciences Ltd., Therexsys deal

...worth 8 percent of Therexsys' shares outstanding, about £4 million (US$6.8 million), to Cobra's founders. Therexsys...
...Therexsys will change its name to Cobra Therapeutics Ltd. Cobra Biosciences Ltd. , Birmingham, U.K. Therexsys Ltd....
BioCentury | Feb 23, 1998
Company News

Therexsys board of directors update

Therexsys Ltd. , Keele, U.K. Business: Gene/Cell therapy Appointed: Michael Carter, EVP and board member of Salick Health Care Inc. WIR Staff...
BioCentury | Dec 15, 1997
Company News

Therexsys management update

Therexsys Ltd., Staffordshire, U.K. Business: Gene/Cell therapy Hired: David Bloxham as CEO, formerly COO of Celltech plc WIR Staff...
BioCentury | Jul 15, 1996
Clinical News

Therexsys regulatory update

...Therexsys said U.S. Patent No. 5,532,143 issued covering its Locus Control Region (LCR) technology. Therexsys has...
...ensure that the introduced gene is expressed in target cells and not in other cells. Therexsys Ltd....
BioCentury | May 6, 1996
Emerging Company Profile

Gryphon Sciences

...Kent, plus Robin Offord and Keith Rose Corporate partners: Icos Corp. , SmithKline Beecham and Therexsys Ltd....
BioCentury | May 6, 1996
Emerging Company Profile

Gryphon: People make proteins

...the vaccine or gene therapy markets only with partners. Grphyon has an ongoing collaboration with Therexsys Ltd....
BioCentury | Dec 4, 1995
Company News

Therexsys other research news

...the manufacture of gene-based medicines. Therexsys is developing non-viral, targeted and regulated gene delivery systems. Therexsys Ltd....
BioCentury | Sep 25, 1995
Emerging Company Profile

Therexsys Ltd.

Therexsys Ltd. Keele, U.K. Technology: Nonviral gene therapy Founded: 1992 by Roger Craig, Frank Grosveld, Michael Dexter, the Medical Research Council (U.K.) and the Cancer Research Campaign (U.K.) University collaborators: Erasmus University (Rotterdam) Corporate partners:...
BioCentury | Sep 25, 1995
Emerging Company Profile

Therexsys: Regulated expression

...to deliver genes successfully is the regulation of expression of the genes in target cells. Therexsys Ltd....
...genes to be transcribed. Thus the LCR technology enables protein expression in specific cells, giving Therexsys...
...of position. Grosveld, now at Erasmus University (Rotterdam), is continuing to collaborate with Therexsys. Self-assembly Therexsys...
Items per page:
1 - 10 of 14